Efficacy of Efavirenz 400mg vs. 600mg Combined With Lamivudine and Tenofovir in Treatment Naive HIV Infection

Summary

The present study will be a randomized controlled study in which 500 treatment-naive HIV patients will be randomized 1:1 to Efaviren 400mg v.s. 600mg combined with lamivudine and tenofovir. The whole cohort will be followed for two years. Efficacy and safety of each regimen will be evaluated throughout the study.

Timeline

Start

2018-04-01

Primary completion

2020-12

Completion

2021-08

Publications

• Hang Q, Ziyan W, Xiaojing S, Min W, Haibo D, Hanhui Y, Zhihao M, Shenghua H, Yun H, Linghua L, Yinzhong S, Yong X, Ping M, Taisheng L. Efavirenz 400 mg vs. 600 mg Combined with Lamivudine and Tenofovir in Treatment-Naive HIV-Infected Patients in China: A Randomized, Multi-Centered, Controlled Trial. Int J Infect Dis. 2026 Jun 2:108859. doi: 10.1016/j.ijid.2026.108859. Online ahead of print.
• Tongtong Y, Shenghua H, Yin W, Lin C, Huanxia L, Chunrong L, Ruifeng Z, Xiaojing Y, Yuan Y, Yuanhong H, Ke Y. Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study. J Acquir Immune Defic Syndr. 2022 Oct 1;91(S1):S1-S7. doi: 10.1097/QAI.0000000000003041.

Drugs

Indications